Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Deferred Revenue (2016 - 2026)

Collegium Pharmaceutical has reported Current Deferred Revenue over the past 7 years, most recently at $667000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $667000.0; the TTM value through Dec 2025 reached $667000.0, changed N/A, while the annual FY2025 figure was $667000.0, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2025 was $667000.0 at Collegium Pharmaceutical, roughly flat from $667000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $172.4 million in Q2 2025 and troughed at $667000.0 in Q3 2025.
  • A 5-year average of $64.1 million and a median of $29.4 million in 2024 define the central range for Current Deferred Revenue.
  • On a YoY basis, Current Deferred Revenue climbed as much as 688.15% in 2025 and fell as far as 97.73% in 2025.
  • Year by year, Current Deferred Revenue stood at $13.2 million in 2021, then surged by 456.13% to $73.6 million in 2022, then skyrocketed by 103.7% to $149.8 million in 2023, then crashed by 80.36% to $29.4 million in 2024, then tumbled by 97.73% to $667000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for COLL at $667000.0 in Q4 2025, $667000.0 in Q3 2025, and $172.4 million in Q2 2025.